<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821895</url>
  </required_header>
  <id_info>
    <org_study_id>T1221</org_study_id>
    <nct_id>NCT04821895</nct_id>
  </id_info>
  <brief_title>Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients</brief_title>
  <acronym>GIST</acronym>
  <official_title>A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registration Study for Wild Type Gastrointestinal Stromal Tumor Patients (TOPICS-GIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The genetic background for cancer treatment may also be different among different areas and&#xD;
      races. There is lack of Taiwanese data of genetic alterations in cancer patients. To&#xD;
      understand the landscape of genetic aberrations of cancer in Taiwan, large scale survey of&#xD;
      the cancer patients is indicated. In this pilot study, the investigators want to evaluate the&#xD;
      landscape of genetic aberrations in cancer patients via oncopaenl test and collect the&#xD;
      clinical data of the patients. The result of the oncopanel test will be returned to patient&#xD;
      and their attending physician for reference of their further treatment. In addition, the&#xD;
      investigators want to correlate the clinical outcome with the genetic aberrations of the&#xD;
      cancer patients in Taiwan. Gastrointestinal stromal tumor (GIST) is a rare cancer compared&#xD;
      with the other solid tumors. C-KIT or PDGFRA mutation is found in approximately 85-90% of&#xD;
      GISTs. Imatinib, a tyrosine kinase inhibitor targeting c-KIT, has been used to treat advanced&#xD;
      GIST successfully since 2000. However, resistance to imatinib may develop either via&#xD;
      secondary mutation of c-KIT or primary resistance to those with wild type c-KIT and PDGFRA.&#xD;
      Although sunitinib and regorafenib have been approved as second and third line of treatment&#xD;
      for advanced GIST, the progression free survival were only 6.8 and 4.8 months, respectively.&#xD;
      The genetic landscape of GIST with wild type c-KIT and PDGFRA was less studied. In the&#xD;
      current study, the investigators want to focus on the GISTs with wild type c-KIT and PDGFRA&#xD;
      to perform the NGS oncopanel for these patients. Then the investigators can understand the&#xD;
      genetic aberrations of these patients (wild type GIST) and help for searching the potential&#xD;
      treatment targets to them.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer is the most common cause of death in Taiwan since 1982. The incidence of cancer is&#xD;
      increasing worldwide, including Taiwan. Cancers in early stage can usually treated with&#xD;
      surgery with a good prognosis. However, the prognosis for recurrent, locally advanced or&#xD;
      metastatic cancers are poor with a shorter survival. Systemic treatments are usually&#xD;
      indicated for these patients. Chemotherapy is the main stay for advanced cancer patients.&#xD;
      However, the advances in the understanding of cancer biology and identification of targeted&#xD;
      therapeutics not only increase the treatment strategies of cancer but also improves the&#xD;
      survival and quality of life of the cancer patients. There are more and more molecularly&#xD;
      targeted therapy developed and approved for the treatment of advanced cancer patients&#xD;
      currently, which makes the beginning of precision cancer medicine. There are more and more&#xD;
      treatments can be used based on the genetic aberrations of the cancers. Because one cancer&#xD;
      type may habor various genetic aberrations, it is not enough to check only one or a few genes&#xD;
      for a patient to choose the adequate treatment. Because the advance in multiplex genomic&#xD;
      test, several NGS-based cancer-associated genetic panel test (oncopanel) have been developed&#xD;
      and used to identify the genetic alterations in each patient, particularly the actionable&#xD;
      genes. Large scale checks of oncopanel have been executed in US. The study showed the genetic&#xD;
      alterations in various cancer types and 11% of the patients had further molecular targeted&#xD;
      therapy based on the result of the oncopanel test. The similar program was done in Japan.&#xD;
      Moreover, the oncopanel test have been implicated in their clinical practice and the cost was&#xD;
      reimbursed by the government in Japan and Korea recently. The precision medicine and such&#xD;
      personalized treatment is the trend for cancer treatment. The trend of such treatment&#xD;
      patterns is also observed in Taiwan. The genetic background for cancer treatment may also be&#xD;
      different among different areas and races. There is lack of Taiwanese data of genetic&#xD;
      alterations in cancer patients. To understand the landscape of genetic aberrations of cancer&#xD;
      in Taiwan, large scale survey of the cancer patients is indicated. In this pilot study, the&#xD;
      investigators want to evaluate the landscape of genetic aberrations in cancer patients via&#xD;
      oncopaenl test and collect the clinical data of the patients. The result of the oncopanel&#xD;
      test will be returned to patient and their attending physician for reference of their further&#xD;
      treatment. In addition, the investigators want to correlate the clinical outcome with the&#xD;
      genetic aberrations of the cancer patients in Taiwan. Gastrointestinal stromal tumor (GIST)&#xD;
      is a rare cancer compared with the other solid tumors. C-KIT or PDGFRA mutation is found in&#xD;
      approximately 85-90% of GISTs. Imatinib, a tyrosine kinase inhibitor targeting c-KIT, has&#xD;
      been used to treat advanced GIST successfully since 2000. However, resistance to imatinib may&#xD;
      develop either via secondary mutation of c-KIT or primary resistance to those with wild type&#xD;
      c-KIT and PDGFRA. Although sunitinib and regorafenib have been approved as second and third&#xD;
      line of treatment for advanced GIST, the progression free survival were only 6.8 and 4.8&#xD;
      months, respectively. The genetic landscape of GIST with wild type c-KIT and PDGFRA was less&#xD;
      studied. In the current study, wthe investigators want to focus on the GISTs with wild type&#xD;
      c-KIT and PDGFRA to perform the NGS oncopanel for these patients. Then the investigators can&#xD;
      understand the genetic aberrations of these patients (wild type GIST) and help for searching&#xD;
      the potential treatment targets to the participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>genetic profiles in gastrointestinal stromal tumor (GIST) patients</measure>
    <time_frame>5-year time frame</time_frame>
    <description>To evaluate the genetic profiles in gastrointestinal stromal tumor (GIST) patients without c-KIT and PDGFRA mutation (wild type) in Taiwan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect clinical data of wild type GIST patients</measure>
    <time_frame>5-year time frame</time_frame>
    <description>Collect clinical data of wild type GIST patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the clinical characteristics, treatment and outcome of wild type GIST patients with the genetic profile in Taiwan.</measure>
    <time_frame>5-year time frame</time_frame>
    <description>To correlate the clinical characteristics, treatment and outcome of wild type GIST patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To help for search the potential targeted agents for the treatment of these wild type GIST patients</measure>
    <time_frame>5-year time frame</time_frame>
    <description>To help for search the potential targeted agents for the treatment of these wild type GIST patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastrointestinal Stromal Tumor (GIST)</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      oncopaenl test&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Wild Type Gastrointestinal stromal tumor (GIST)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically confirmed GIST.&#xD;
&#xD;
          2. The tumors can be resected, unresectable, recurrent or metastatic and the patients had&#xD;
             ever received, are receiving or will receive systemic treatment (adjuvant, neoadjuvant&#xD;
             or salvage TKI or other targeted agents)&#xD;
&#xD;
          3. The tumors were tested for wild type c-KIT and PDGFRA.&#xD;
&#xD;
          4. There are archived tumor samples available or the patients agree to do tumor biopsy&#xD;
             for oncopanel test if there is no tumor sample or not enough tumor sample available.&#xD;
&#xD;
          5. The patients who are systemic treatment na√Øve or have received prior systemic&#xD;
             treatment are all eligible.&#xD;
&#xD;
          6. Age - the legal age.&#xD;
&#xD;
          7. Life expectancy greater than 6 months&#xD;
&#xD;
          8. Capable of understanding and complying with the protocol requirements and signed&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if they meet any of the following criteria:&#xD;
&#xD;
               1. Inability and unwillingness to give informed consent&#xD;
&#xD;
               2. Patients do not agree to provide archived tumor samples and blood samples or they&#xD;
                  do not agree to do tumor biopsy when archived tumor samples are not available.&#xD;
&#xD;
               3. Patients refused for collection of clinical data and follow up.&#xD;
&#xD;
               4. Mental status is not fit for further treatment or data collection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-Jen Tsai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li-Tzong Chen, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>leochen@nhri.org.tw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui-Jen Tsai, M.D.</last_name>
    <phone>886-6-2083422</phone>
    <phone_ext>65149</phone_ext>
    <email>hjtsai@nhri.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li-Tzong Chen, Ph.D</last_name>
    <phone>886-6-2083422</phone>
    <phone_ext>65110</phone_ext>
    <email>leochen@nhri.org.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chieh-Han Chuang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I-Shu Chen, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Yaun Bai, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan-Shen Shan, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chung -Hsin Tsai, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching Yao Yang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>De-Chuan Chan, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Stromal Tumor(GIST)</keyword>
  <keyword>Oncogenetic Panel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

